At 5-years EES was superior with regards to efficacy and safety to PES in non-diabetic patients. In diabetic patients a late trend towards reduction of MACE was observed with EES compared to PES, mainly driven by a lower rate of TVR.
Background: We sought to investigate the long-term outcomes of an abluminal groove-filled biodegradable polymer sirolimus-eluting stent FIREHAWK (MicroPort Medical, Shanghai, China) compared to an everolimus-eluting stent (EES) XIENCE V in the randomized TARGET I trial.
Methods: A total of 458 patients with single de novo native coronary lesions < ¼24 mm in length and a coronary artery >¼2.25 to < ¼4.0 mm in diameter were enrolled in the TARGET I study, a prospective, randomized, non-inferiority trial. The primary endpoint was in-stent late lumen loss (LLL) at 9-month follow-up. The secondary endpoint, target lesion failure (TLF), was defined as the composite of cardiac death, target vessel myocardial infarction (TV-MI), and ischemia-driven target lesion revascularization (iTLR). Clinical follow-up was scheduled at 1-, 6-and 12-month, and annually up to 5 years for all enrolled patients. All adverse clinical events were adjudicated by an independent committee. Results: Previously reported results demonstrated FIREHAWK stent was non-inferior to XIENCE V EES for the primary endpoint of 9-month in-stent LLL (0.13AE0.24 mm vs. 0.13AE0.18 mm, p¼0.94; difference and 95% confidence interval 0.00 [-0.04, 0.04] mm; p for non-inferiority < 0.0001), and had a comparable clinical outcome at 2 years. There were still no significant differences between the two groups up to 3 years, and no definite/probable stent thrombosis occurred in FIREHAWK group. (Table) Conclusions: In the multicenter randomized TARGET I trial, the 3-year follow-up results confirmed that the novel FIREHAWK stent had a durable safety and efficacy profile, which was comparable to the XIENCE V EES for the treatment of single de novo native coronary lesions. (ClinicalTrials.gov Identifier: NCT01196819)
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Background: Drug-eluting stents with biodegradable polymers have been developed to reduce the risk of very late adverse events. Distinct studies have indicated noninferiority of the biodegradable polymer-coated biolimus-eluting stent (NoboriÔ; BES) compared to the durable polymer-coated everolimus-eluting stent (XienceÔ or PromusÔ; EES) with regards to safety and efficacy at 1 year. However, these trials were not powered to detect differences in low-frequency events. Methods: The all-comers COMPARE II and NEXT clinical trials randomly assigned 5942 patients to BES or EES and is at present the largest pooled analysis of BES in all-comers requiring percutaneous coronary intervention (PCI). The pre-specified composite endpoint was target vessel failure (TVF) defined as cardiac death, target vessel related myocardial infarction (MI), or clinical-indicated target vessel revascularization (TVR-CD). Results: The pooled unadjusted 1-year clinical outcomes of the 5942 study patients (8094 lesions) are tabulated. Covariate adjusted analyses accounting for baseline imbalances between trials confirmed non-significant differences between stent type and clinical outcomes. The trend for a higher definite stent thrombosis rate in the BES group was by multivariate analysis less prominent (HR 2.05 [CI95% 0.75-5.60]; p¼0.16).
Conclusions:
At 1-year the biodegradable polymer-coated BES has similar safety and efficacy outcomes as the durable polymer-coated EES. Longer follow-up data is needed to determine the role of biodegradable polymer-coated BES in real world clinical practice.
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Lower Background: These are the first long-term randomized adjudicated trial data of five year results of the Genous bio-engineered endothelial progenitor cell capturing stent (OrbusNeich BV, Fort Lauderdale, FL, USA) compared with a paclitaxel-eluting stent(PES). Methods: In this prospective randomized trial, patients with de-novo coronary artery lesions carrying a high risk of restenosis (chronic total occlusion,lesion length > 23mm,vessel diameter < 2.8mm or any lesion in a diabetic patient) were randomized 1:1 to the Genous or a PES. The current primary endpoint is adjudicated target vessel failure (TVF) at 5-years, a composite of cardiac death, myocardial infarction (MI) and target vessel revascularization. Clinical event rates were estimated by Kaplan-Meier method and compared with a log-rank test. Results: A total of 193 patients were included with complete follow-up in 97% of the subjects. The primary endpoint of TVF was similar at 5 years with Genous 23.8% vs 
